Новости: Рекомендации по эндоскопическому лечению пациентов с дисплазией и внутрислизистым раком при пищеводе Баррета.

Полный текст статьи:

Американское общество гастроинтестинальной эндоскопии предлагает ознакомиться с новыми рекомендациями по эндоскопическому лечению пациентов с дисплазией и внутрислизистым раком при пищеводе Баррета.

Пищевод барретта (BE) определяется заменой нормального плоскоклеточного эпителия дистального пищевода метапластическим столбчатым эпителием кишечного типа.

Читать полный текст абстракта статьи...

References

• American Gastroenterological Association, Spechler, S.J., Sharma, P., Souza, R.F. et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140: 1084–1091

• Shaheen, N.J., Falk, G.W., Iyer, P.G. et al. ACG clinical guideline: diagnosis and management of Barrett's esophagus. (quiz 51)Am J Gastroenterol. 2016; 111: 30–50

• Wani, S., Rubenstein, J.H., Vieth, M. et al. Diagnosis and management of low-grade dysplasia in Barrett's esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology. 2016; 151: 822–835

• Rubenstein, J.H. and Shaheen, N.J. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015; 149: 302–317

• Hur, C., Miller, M., Kong, C.Y. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119: 1149–1158

• Pohl, H. and Welch, H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97: 142–146

• Lepage, C., Rachet, B., Jooste, V. et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008; 103: 2694–2699

• Ronkainen, J., Aro, P., Storskrubb, T. et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825–1831

• Zagari, R.M., Fuccio, L., Wallander, M.A. et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008; 57: 1354–1359

• Wani, S., Falk, G., Hall, M. et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. (quiz e226)Clin Gastroenterol Hepatol. 2011; 9: 220–227

• Wani, S., Falk, G.W., Post, J. et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology. 2011; 141: 1179–1186

• Rastogi, A., Puli, S., El-Serag, H.B. et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008; 67: 394–398

• Hvid-Jensen, F., Pedersen, L., Drewes, A.M. et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011; 365: 1375–1383

• Wani, S., Muthusamy, V.R., Shaheen, N.J. et al. Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointest Endosc. 2017; 86: 1–17

• Wani, S. and Sharma, P. Challenges with endoscopic therapy for Barrett's esophagus. Gastroenterol Clin North Am. 2015; 44: 355–372

• Shaheen, N.J., Sharma, P., Overholt, B.F. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360: 2277–2288

• Phoa, K.N., van Vilsteren, F.G., Weusten, B.L. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014; 311: 1209–1217

• Wolf, W.A., Pasricha, S., Cotton, C. et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett's esophagus. Gastroenterology. 2015; 149: 1752–1761

• Pech, O., Behrens, A., May, A. et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008; 57: 1200–1206

• Orman, E.S., Li, N., and Shaheen, N.J. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 1245–1255

• Phoa, K.N., Pouw, R.E., van Vilsteren, F.G. et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013; 145: 96–104

• Qumseya, B.J., Wani, S., Desai, M. et al. adverse events after radiofrequency ablation in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016; 14: 1086–

• Wani, S., Drahos, J., Cook, M.B. et al. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc. 2014; 79: 224–232

• Sultan, S., Falck-Ytter, Y., and Inadomi, J.M. The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol. 2013; 11: 329–332

• Moher, D., Liberati, A., Tetzlaff, J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269

• Shea, B.J., Grimshaw, J.M., Wells, G.A. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007; 7: 10

• Yachimski, P., Wani, S., Givens, T. et al. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2015; 13: 84–90

• Hur, C., Wittenberg, E., Nishioka, N.S. et al. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus. Dig Dis Sci. 2005; 50: 116–125

• Rosmolen, W.D., Boer, K.R., de Leeuw, R.J. et al. Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus. Endoscopy. 2010; 42: 525–531

• Hur, C., Choi, S.E., Rubenstein, J.H. et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012; 143: 567–575

• Phoa, K.N., Rosmolen, W.D., Weusten, B.L. et al. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF-trial). Gastrointest Endosc. 2017; 86: 120–129

• Pohl, H., Sonnenberg, A., Strobel, S. et al. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. Gastrointest Endosc. 2009; 70: 623–631

• Qumseya, B.J., Wani, S., Gendy, S. et al. Disease progression in Barrett's low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017; 112: 849–865

• Duits, L.C., van der Wel, M.J., Cotton, C.C. et al. Patients with Barrett’s esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia. Gastroenterology. 2017; 152: 993–1001

• Schlemper, R.J., Riddell, R.H., Kato, Y. et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000; 47: 251–255

• Bosman, F., Carneiro, F., Hruban, R.H. et al. WHO classification of gastrointestinal tumors. IARC, Lyon, France; 2010

• Montgomery, E., Bronner, M.P., Goldblum, J.R. et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001; 32: 368–378

• Wani, S., Mathur, S.C., Curvers, W.L. et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol. 2010; 8: 783–788

• Curvers, W.L., ten Kate, F.J., Krishnadath, K.K. et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010; 105: 1523–1530

• Vennalaganti, P., Kanakadandi, V., Goldblum, J.R. et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett's esophagus. Gastroenterology. 2017; 152: 564–570

• Wani, S., Muthusamy, V.R., Shaheen, N.J. et al. Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol. 2017; 112: 1032–1048

• Small, A.J., Araujo, J.L., Leggett, C.L. et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett's esophagus and confirmed low-grade dysplasia. Gastroenterology. 2015; 149: 567–576.e3

• Kestens, C., Offerhaus, G.J., van Baal, J.W. et al. Patients with Barrett's esophagus and persistent low-grade dysplasia have an increased risk for high-grade dysplasia and cancer. Clin Gastroenterol Hepatol. 2016; 14: 956–962

• Tavakkoli, A., Appelman, H., Beer, D. et al. Risk factors for progression of Barrett's esophagus with low-grade dysplasia. Gastroenterology. 2016; 150: S177

• Overholt, B.F., Lightdale, C.J., Wang, K.K. et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005; 62: 488–498

• Wu, J., Pan, Y.M., Wang, T.T. et al. Endotherapy versus surgery for early neoplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc. 2014; 79: 233–241

• Schmidt, M., Bodnar, A., Irani, S. et al. Multidisciplinary treatment of T1a adenocarcinoma in Barrett's esophagus: contemporary comparison of endoscopic and surgical treatment. ([abstract])Gastrointest Endosc. 2014; 79: AB495

• Wani, S., Early, D., Edmundowicz, S. et al. Management of high-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol. 2012; 10: 704–711

• Bennett, C., Vakil, N., Bergman, J. et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012; 143: 336–346

• Dunbar, K.B. and Spechler, S.J. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. (quiz 863)Am J Gastroenterol. 2012; 107: 850–862

• Fujii-Lau, L.L., Cinnor, B., Shaheen, N.J. et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis. Endosc Int Open. 2017; 05: E1–E20

• Krishnamoorthi, R., Singh, S., Ragunathan, K. et al. Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointest Endosc. 2016; 83: 1090–1106

• Pasricha, S., Bulsiewicz, W.J., Hathorn, K.E. et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014; 12: 1840–1847

• Komanduri, S., Kahrilas, P.J., Krishnan, K. et al. Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol. 2017; 112: 556–566

• Leers, J.M., DeMeester, S.R., Oezcelik, A. et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011; 253: 271–278

• Tomizawa, Y., Iyer, P.G., Wong Kee Song, L.M. et al. Safety of endoscopic mucosal resection for Barrett's esophagus. (quiz 1448)Am J Gastroenterol. 2013; 108: 1440–1447

• Pech, O., May, A., Manner, H. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014; 146: 652–660

• Wani, S., Abrams, J., Edmundowicz, S.A. et al. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett's esophagus patients with visible and flat neoplasia: a multicenter cohort study. Dig Dis Sci. 2013; 58: 1703–1709

• Wani, S., Sayana, H., and Sharma, P. Endoscopic eradication of Barrett's esophagus. Gastrointest Endosc. 2010; 71: 147–166

• Mino-Kenudson, M., Hull, M.J., Brown, I. et al. EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. (quiz 767, 769)Gastrointest Endosc. 2007; 66: 660–666

• Sharma, P., Katzka, D.A., Gupta, N. et al. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015; 149: 1599–1606

• Manner, H., Rabenstein, T., Pech, O. et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy. 2014; 46: 6–12

• Desai, M., Saligram, S., Gupta, N. et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017; 85: 482–495

• Anders, M., Bahr, C., El-Masry, M.A. et al. Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection. Gut. 2014; 63: 1535–1543

• Small, A.J., Sutherland, S.E., Hightower, J.S. et al. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. Gastrointest Endosc. 2015; 81: 1158–1166

• Vaccaro, B.J., Gonzalez, S., Poneros, J.M. et al. Detection of intestinal metaplasia after successful eradication of Barrett's Esophagus with radiofrequency ablation. Dig Dis Sci. 2011; 56: 1996–2000

• Cotton, C.C., Wolf, W.A., Pasricha, S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location. Gastrointest Endosc. 2015; 81: 1362–1369

• Pasricha, S., Cotton, C., Hathorn, K.E. et al. Effects of the learning curve on efficacy of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2015; 149: 890–896

• van Vilsteren, F.G., Pouw, R.E., Herrero, L.A. et al. Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy. 2012; 44: 4–12

• Fudman, D.I., Lightdale, C.J., Poneros, J.M. et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc. 2014; 80: 71–77